nach oben

Erschienen in:

02.03.2019 | Preclinical study

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

verfasst von: Jangsoon Lee, Bora Lim, Troy Pearson, Kuicheon Choi, Jon A. Fuson, Chandra Bartholomeusz, Linda J. Paradiso, Thomas Myers, Debu Tripathy, Naoto T. Ueno

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus, it does not respond to receptor-targeted treatments. TNBC has higher recurrence, metastasis, and mortality rates than other subtypes of breast cancer. Mounting data suggest that the MAPK (also known as RAS-RAF-MEK-ERK) pathway is an important therapeutic target in TNBC.

Methods

To evaluate anti-tumor and anti-metastasis efficacy of E6201, we used cell proliferation assay, soft agar assay, cell cycle assay, Annexin V staining assay, immunoblotting analysis, immunohistochemistry, migration assay, invasion assay, mammary fat pad xenograft, and experimental and spontaneous metastasis xenograft models. We also evaluated the anti-tumor efficacy of E6201 plus CDK4/6 inhibitor, mTOR inhibitor, or ATR inhibitor.

Results

E6201 inhibited TNBC cell colony formation, migration, and invasion in a dose-dependent manner. E6201 induced G1 cell cycle arrest and apoptosis. E6201 inhibited TNBC xenograft growth and inhibited TNBC lung metastasis and improved mouse survival in experimental metastasis and spontaneous metastasis assays. Immunohistochemical staining demonstrated that E6201 decreased the metastatic burden in the lung and decreased phosphorylated ERK expression in a dose-dependent manner. Combination of E6201 with CDK4/6 inhibitor or mTOR inhibitor enhanced E6201’s in vitro anti-tumor efficacy.

Conclusion

These results indicate that E6201 exhibits anti-tumor efficacy against TNBC in vitro and anti-metastasis efficacy against TNBC in vivo. These results provide a rationale for further clinical development of E6201 as a MAPK-pathway-targeted therapy for TNBC.

Nur mit Berechtigung zugänglich

Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17(3):173–176CrossRefPubMed

Brouckaert O, Wildiers H, Floris G, Neven P (2012) Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 4:511–520PubMedPubMedCentral

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434CrossRefPubMed

Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):103–119CrossRefPubMedPubMedCentral

Eroglu Z, Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 8(1):48–56CrossRefPubMedPubMedCentral

Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP et al (2016) MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Dev Ther 10:43–52

Yang Y, Liu YH, Sun X, Yu MW, Yang L, Cheng PY et al (2017) Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. Curr Med Res Opin 33(9):1663–1675CrossRefPubMed

Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J et al (2015) MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 14(12):2773–2781CrossRefPubMedPubMedCentral

Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C et al (2015) Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer. J Cancer 6(12):1306–1319CrossRefPubMedPubMedCentral

10.

Muramoto K, Goto M, Inoue Y, Ishii N, Chiba K, Kuboi Y et al (2010) E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther 335(1):23–31CrossRefPubMed

11.

Ikemori-Kawada M, Inoue A, Goto M, Wang YJ, Kawakami Y (2012) Docking simulation study and kinase selectivity of f152A1 and its analogs. J Chem Inf Model 52(8):2059–2068CrossRefPubMed

12.

Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J et al (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75CrossRefPubMedPubMedCentral

13.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L et al (2018) Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases. Drug Metab Dispos 46(5):658–666CrossRefPubMedPubMedCentral

14.

Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A et al (2018) Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. Br J Cancer 118(12):1580–1585CrossRefPubMedPubMedCentral

15.

Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR et al (2016) The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Res 76(6):1528–1537CrossRefPubMedPubMedCentral

16.

Carragher NO, Frame MC (2004) Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 14(5):241–249CrossRefPubMed

17.

Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K (2005) Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 5(2):215–229CrossRefPubMed

18.

Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P et al (2010) Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10(9):903–917. https://doi.org/10.4161/cbt.10.9.13273 CrossRefPubMedPubMedCentral

19.

Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R et al (2008) Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6(1):42–52. https://doi.org/10.1158/1541-7786.MCR-07-0080 CrossRefPubMed

20.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B et al (2012) MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 26(4):778–787. https://doi.org/10.1038/leu.2011.287 CrossRefPubMed

21.

Hermanson DL, Das SG, Li Y, Xing C (2013) Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIbeta downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol 84(2):236–243. https://doi.org/10.1124/mol.113.086140 CrossRefPubMedPubMedCentral

22.

Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z et al (2014) Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res 182(6):618–625. https://doi.org/10.1667/RR13856.1 CrossRefPubMedPubMedCentral

23.

Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA (2016) Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther 15(12):3015–3027. https://doi.org/10.1158/1535-7163.mct-16-0017 CrossRefPubMedPubMedCentral

24.

25.

Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13(9):679–692. https://doi.org/10.1038/nri3495 CrossRefPubMed

26.

ClinicalTrials.gov (2019) Search of: MEK inhibitor|interventional studies|breast cancer—list results—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=breast+cancer&term=MEK+inhibitor&type=Intr&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=&sort=

27.

Cheng Y, Tian H (2017) Current Development status of MEK inhibitors. Molecules 22(10):1551CrossRefPubMedCentral

28.

Albanell J, Elvin JA, Ali SM, Schrock AB, Chung J, Vergilio J-A et al (2017) BRAF: an emerging target for triple-negative breast cancer. J Clin Oncol 35(15_suppl):1099–1099CrossRef

29.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC et al (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116(5):1234–1242CrossRefPubMedPubMedCentral

30.

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238–10246CrossRefPubMed

31.

Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4):383–388CrossRefPubMed

32.

Maiello MR, D’Alessio A, Bevilacqua S, Gallo M, Normanno N, De Luca A (2015) EGFR and MEK blockade in triple negative breast cancer cells. J Cell Biochem 116(12):2778–2785CrossRefPubMed

33.

Nakai K, Hung MC, Yamaguchi H (2016) A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res 6(8):1609–1623PubMedPubMedCentral

34.

Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K et al (2012) MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther 11(2):360–369CrossRefPubMed

35.

Chen X, Zheng Z, Chen L, Zheng H (2017) MAPK, NFkappaB, and VEGF signaling pathways regulate breast cancer liver metastasis. Oncotarget 8(60):101452–101460PubMedPubMedCentral

36.

Shao GL, Wang MC, Fan XL, Zhong L, Ji SF, Sang G et al (2018) Correlation between Raf/MEK/ERK signaling pathway and clinicopathological features and prognosis for patients with breast cancer having axillary Lymph node metastasis. Technol Cancer Res Treat. https://doi.org/10.1177/1533034617754024 CrossRefPubMedPubMedCentral

37.

Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B et al (2017) Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer. Clin Cancer Res 23(16):4780–4792CrossRefPubMedPubMedCentral

38.

Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E et al (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11(3):720–729CrossRefPubMed

39.

Nagaria TS, Shi C, Leduc C, Hoskin V, Sikdar S, Sangrar W et al (2017) Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. Oncotarget 8(46):80804–80819CrossRefPubMedPubMedCentral

40.

Sato N, Wakabayashi M, Nakatsuji M, Kashiwagura H, Shimoji N, Sakamoto S et al (2017) MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochem Biophys Res Commun 489(4):484–489CrossRefPubMed

41.

Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS et al (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149(2):307–321CrossRefPubMedPubMedCentral

42.

Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R et al (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69(2):565–572CrossRefPubMedPubMedCentral

43.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26(13):2139–2146CrossRefPubMedPubMedCentral

44.

Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22(22):4456–4462CrossRefPubMed

45.

Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K et al (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15(14):4649–4664CrossRefPubMed

46.

Leung EY, Kim JE, Askarian-Amiri M, Rewcastle GW, Finlay GJ, Baguley BC (2014) Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines. PLoS ONE 9(8):e105792CrossRefPubMedPubMedCentral

47.

Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM et al (2017) Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro Oncol 19(11):1481–1493CrossRefPubMedPubMedCentral

48.

Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC et al (2018) Combined BRAF, EGFR, and MEK Inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8(4):428–443CrossRefPubMedPubMedCentral

49.

Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A et al (2016) Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Ann Oncol 27(6):1123–1128CrossRefPubMed

50.

Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F et al (2016) Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget 7(26):39595–39608CrossRefPubMedPubMedCentral

51.

Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G et al (2012) The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat 131(2):425–436CrossRefPubMed

52.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS et al (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4(2):232–245CrossRefPubMed

53.

Brufsky A, Miles D, Zvirbule Z, Eniu A, Lopez-Miranda E, Seo JH et al (2018) Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I. Cancer Research. SABCS17-P5-21-01

54.

Chumsri S, Polley M-Y, Anderson SL, O’Sullivan CCM, Colon-Otero G, Knutson KL et al (2018) Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer. J Clin Oncol 36(5_suppl):TPS17–TPS17CrossRef

Titel: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
verfasst von: Jangsoon Lee
Bora Lim
Troy Pearson
Kuicheon Choi
Jon A. Fuson
Chandra Bartholomeusz
Linda J. Paradiso
Thomas Myers
Debu Tripathy
Naoto T. Ueno
Publikationsdatum: 02.03.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05166-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Corneal features in trastuzumab emtansine treatment: not a rare occurrence

Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors

Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers

A high-risk luminal A dominant breast cancer subtype with increased mobility

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie